ADC205 Tablets Received Approval for Drug Clinical Trial
January 20, 2026
Source: drugdu
32
Jiangsu Aidea Pharma Announcement: The company has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (NMPA) on January 18, 2026. The notice approves clinical trials for the company's investigational Class 2.3 modified new drug, Dolutegravir/Lamivudine/Tenofovir Tablets (ADC205), which is dedicated to the field of anti-HIV/AIDS.
https://finance.eastmoney.com/a/202601193623367035.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- 20-Valent Pneumococcal Vaccine Approved for Clinical Trials January 20, 2026
- Sifang Optoelectronics makes strategic investment in Changhe Biotechnology January 20, 2026
- Mingde Bio plans to acquire a 51% stake in Hunan Lanyi through capital increase and acquisition January 20, 2026
- accelerating the transition of CLL treatment into a “chemotherapy-free era”. January 20, 2026
- Clinical trials successful, development terminated. January 20, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
